We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2022 to May 2024
By Joe Hoppe
AstraZeneca PLC said Thursday that its Lynparza treatment has been approved in the European Union for patients with early breast cancer.
The Anglo-Swedish pharmaceutical company said the treatment is the first PARP inhibitor--a type of targeted cancer drug--to improve overall survival in early-stage, high-risk breast cancer.
Lynparza has been approved for use either as a treatment on its own or in combination with endocrine therapy.
In a trial, the treatment demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% when compared with a placebo, and overall survival by 32% versus a placebo, AstraZeneca said. The drug's safety and tolerability in the trial was also in line with prior results, it added.
The treatment was approved in the U.S. for treating some forms of high-risk early breast cancer in March.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
August 04, 2022 02:39 ET (06:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
